FTC Moves To Squash $3.1B CLS-Talecris Merger

Law360, New York (May 28, 2009, 12:00 AM EDT) -- The Federal Trade Commission has officially moved to block blood plasma-derived therapeutics company CSL Ltd.'s proposed $3.1 billion acquisition of rival Talecris Biotherapeutics, a deal the agency claims will reduce competition in the U.S. market for plasma-derivative protein therapies.

In an administrative complaint filed Wednesday, the FTC alleges the proposed acquisition would consolidate the market for protein therapies, increase the likelihood of collusion, tighten supply relative to demand and drive up prices.

Although the FTC said it had authorized its staff to seek a preliminary injunction...
To view the full article, register now.